FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2156218744> ?p ?o ?g. }

• W2156218744 abstract "THE USE of animal models to define and test novel immunotherapeutic approaches for type I autoimmune diabetes (IDDM) has elicited increasing interest. The goal is to selectively influence the autoimmune process in the islets of Langerhans by dampening or increasing certain immune functions without significantly affecting the overall immune competence of the host. In contrast to generalized systemic immunosuppression using chemotherapeutic drug regimens, this novel strategy attempts to identify and then modulate key molecules and regulators that are specific only for the pathogenesis of IDDM. The appealing aspect is that side effects can be kept to a minimum, and therefore a large collective of individuals at risk for developing IDDM could be treated. For testing such approaches quickly, small animal models are the best tools. The focus of this article is to describe more recent findings using a transgenic mouse model, the RIP-LCMV mice, and discuss their relevance for pointing out strengths and pitfalls in future immunotherapy of human IDDM. The pathogenesis of IDDM is a multifactorial process that is influenced by genetic host factors as well as environmental influences, for example viral infections. It involves a chain of immunologic events that have to occur before enough insulin-producing b cells are destroyed to generate clinical symptoms. Many steps of this process have been defined through studies on animal models or humans. The key events are displayed in Fig 1 and numbered 1 through 10. Most of the stages allow selective immunologic interventions and could form the basis for efficient immunotherapy. The purpose of this article is to identify the key stages that are suited for immunomodulatory approaches (Fig 1) and discuss the supporting evidence from the rat insulin promoter-lymphocytic choriomeningitis (RIP-LCMV) and other models, including the relevance for potential therapeutic approaches. In this way, I hope to shine more light on the multiple facets of immunotherapy for IDDM and provide some ideas and guidelines for future drug development and clinical testing in prediabetic or recently diabetic individuals. The RIP-LCMV model for autoimmune diabetes that will form the basis for the discussions in this article was developed in 1991 independently by Michael Oldstone and Rolf Zinkernagel and Hans Hengartner. These transgenic mice express proteins from LCMV under control of the RIP in their b cells. Expression of the proteins as target self-antigens does not lead to disease or islet cell dysfunction. However, the animals are not tolerant to the viral proteins because infection with LCMV induces IDDM in 90 to 100% of the transgenic mice but never in nontransgenic controls. IDDM is characterized by lymphocytic infiltration of islets by CD4 and CD8 cytotoxic T lymphocytes (CTL) resulting in their destruction and does not occur in the absence of CTL. Animals from lines that develop IDDM more slowly require participation of CD4 and CD8 lymphocytes for disease development and some also exhibit auto-antibodies to GAD and insulin (M.G. von Herrath, T. Dyrberg, W. Hagopian, and M.B.A. Oldstone, unpublished results), which indicate that the autoimmune process spreads from the initial target LCMV antigen. The advantage of this diabetes model is that the initiating self-antigen is known, autoreactive lymphocytes can be precisely tracked, and the time-point for induction of autoimmunity can be experimentally chosen. It exhibits most features that have been found or postulated for human IDDM and offers a suitable therapeutic window between triggering of disease (LCMV infection) and clinical IDDM (2 weeks to 6 months)." @default.
• W2156218744 created "2016-06-24" @default.
• W2156218744 creator A5015949107 @default.
• W2156218744 date "1998-12-01" @default.
• W2156218744 modified "2023-09-25" @default.
• W2156218744 title "Selective immunotherapy of iddm: a discussion based on new findings from the RIP-LCMV model for autoimmune diabetes" @default.
• W2156218744 cites W1494153135 @default.
• W2156218744 cites W1495089934 @default.
• W2156218744 cites W1496041070 @default.
• W2156218744 cites W1502521547 @default.
• W2156218744 cites W1506430118 @default.
• W2156218744 cites W1594237361 @default.
• W2156218744 cites W1595946831 @default.
• W2156218744 cites W1603504717 @default.
• W2156218744 cites W1633194666 @default.
• W2156218744 cites W1655828737 @default.
• W2156218744 cites W1669446079 @default.
• W2156218744 cites W1672597967 @default.
• W2156218744 cites W1743939398 @default.
• W2156218744 cites W1760886018 @default.
• W2156218744 cites W1775395314 @default.
• W2156218744 cites W1802879891 @default.
• W2156218744 cites W1887207389 @default.
• W2156218744 cites W1899014224 @default.
• W2156218744 cites W1905494569 @default.
• W2156218744 cites W1924045177 @default.
• W2156218744 cites W1929904751 @default.
• W2156218744 cites W1968274103 @default.
• W2156218744 cites W1972735675 @default.
• W2156218744 cites W1975485580 @default.
• W2156218744 cites W1978060006 @default.
• W2156218744 cites W1985946203 @default.
• W2156218744 cites W1988317772 @default.
• W2156218744 cites W1989090634 @default.
• W2156218744 cites W1990204841 @default.
• W2156218744 cites W1991204721 @default.
• W2156218744 cites W1993457053 @default.
• W2156218744 cites W1993780439 @default.
• W2156218744 cites W1995201985 @default.
• W2156218744 cites W1996109184 @default.
• W2156218744 cites W2003292000 @default.
• W2156218744 cites W2008120575 @default.
• W2156218744 cites W2010484159 @default.
• W2156218744 cites W2013642092 @default.
• W2156218744 cites W2019398337 @default.
• W2156218744 cites W2021307419 @default.
• W2156218744 cites W2022410707 @default.
• W2156218744 cites W2023236971 @default.
• W2156218744 cites W2025445086 @default.
• W2156218744 cites W2027729283 @default.
• W2156218744 cites W2034882151 @default.
• W2156218744 cites W2037832428 @default.
• W2156218744 cites W2039183873 @default.
• W2156218744 cites W2040838085 @default.
• W2156218744 cites W2041404362 @default.
• W2156218744 cites W2045758494 @default.
• W2156218744 cites W2046749316 @default.
• W2156218744 cites W2049998759 @default.
• W2156218744 cites W2050231629 @default.
• W2156218744 cites W2050359848 @default.
• W2156218744 cites W2050473688 @default.
• W2156218744 cites W2051754218 @default.
• W2156218744 cites W2054093771 @default.
• W2156218744 cites W2055724291 @default.
• W2156218744 cites W2057328452 @default.
• W2156218744 cites W2059059286 @default.
• W2156218744 cites W2071756824 @default.
• W2156218744 cites W2074012831 @default.
• W2156218744 cites W2075963617 @default.
• W2156218744 cites W2077062089 @default.
• W2156218744 cites W2080636087 @default.
• W2156218744 cites W2081174864 @default.
• W2156218744 cites W2088350742 @default.
• W2156218744 cites W2090307694 @default.
• W2156218744 cites W2092066206 @default.
• W2156218744 cites W2096094429 @default.
• W2156218744 cites W2104809506 @default.
• W2156218744 cites W2104987352 @default.
• W2156218744 cites W2112812475 @default.
• W2156218744 cites W2118600639 @default.
• W2156218744 cites W2125985469 @default.
• W2156218744 cites W2136135274 @default.
• W2156218744 cites W2136404424 @default.
• W2156218744 cites W2136511409 @default.
• W2156218744 cites W2138212565 @default.
• W2156218744 cites W2143188779 @default.
• W2156218744 cites W2150371745 @default.
• W2156218744 cites W2151984697 @default.
• W2156218744 cites W2152237445 @default.
• W2156218744 cites W2158500407 @default.
• W2156218744 cites W2159162888 @default.
• W2156218744 cites W2161817457 @default.
• W2156218744 cites W2162703862 @default.
• W2156218744 cites W2162888477 @default.
• W2156218744 cites W2163802114 @default.
• W2156218744 cites W2167357790 @default.
• W2156218744 cites W2171986697 @default.
• W2156218744 cites W2409839617 @default.
• W2156218744 cites W82513444 @default.
• W2156218744 cites W91308838 @default.

• next